DB2313 |
Catalog No.GC62222
One-Click Copy Product Info
|
DB2313 is a potent transcription factor PU.1 inhibitor with an IC50 of 14nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2170606-74-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
DB2313 is a potent transcription factor PU.1 inhibitor with an IC50 of 14nM[1]. DB2313 disrupts the interaction of PU.1 with target gene promoters[2]. PU.1, a critical transcription factor in the hematopoietic system, plays key roles in myeloid and lymphoid cell differentiation, maintenance of hematopoietic stem cell functions, and the development of acute myeloid leukemia (AML)[3]. DB2313 is usually used in research related to AML and inflammation[4].
In vitro, DB2313 (10μg/ml; 72h) significantly inhibited the proliferation, migration, and invasion of GBM cells (U118MG and U87MG)[5].
In vivo, DB2313 (17mg/kg; every 2 days via intraperitoneal injection for 12 days) significantly suppressed tumor growth and enhanced the recruitment of CD4+ T helper 1 (Th1) and cytotoxic T/natural killer (NK) cells into tumors in the B16-OVA melanoma mouse model[6]. DB2313 (8mg/kg; intranasal administration; 5 days/week for 3 weeks) decreased airway mucus-secreting cell numbers and small airway collagen deposition, and significantly reduced airway hyperresponsiveness in a house dust mite (HDM)-induced experimental asthma mouse model[7].
References:
[1] Antony-Debre I, Paul A, Leite J, et al. Pharmacological inhibition of the transcription factor PU.1 in leukemia. J Clin Invest. 2017;127(12):4297-4313.
[2] Tu J, Chen W, Fang Y, et al. PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes. Ann Rheum Dis. 2023;82(2):198-211.
[3] Fisher RC, Scott EW. Role of PU.1 in hematopoiesis. Stem Cells. 1998;16(1):25-37.
[4] Tu X, Kim RY, Brown AC, et al. Airway and parenchymal transcriptomics in a novel model of asthma and COPD overlap. J Allergy Clin Immunol. 2022;150(4):817-829.e6.
[5] Zhang S, Zhao S, Qi Y, et al. SPI1-induced downregulation of FTO promotes GBM progression by regulating pri-miR-10a processing in an m6A-dependent manner. Mol Ther Nucleic Acids. 2022;27:699-717.
[6] Sleapnicov N, Ha SD, Zhong SJ, et al. Inhibition of the Transcription Factor PU.1 Suppresses Tumor Growth in Mice by Promoting the Recruitment of Cytotoxic Lymphocytes Through the CXCL9-CXCR3 Axis. Cancers (Basel). 2025;17(16):2684.
[7] Tu X, Gomez HM, Kim RY, et al. Airway and parenchyma transcriptomics in a house dust mite model of experimental asthma. Respir Res. 2023;24(1):32.
| Cell experiment [1]: | |
Cell lines | glioma cell lines U87MG and U118MG |
Preparation Method | The glioma cell lines U87MG and U118MG were cultured in DMEM containing 10% fetal bovine serum and 1% penicillin-streptomycin. All cells were maintained in a humidified incubator with 5% CO2 at 37℃. The cells were routinely tested for mycoplasma contamination. 2000 GBM cells were seeded in 96-well plates and measured cell viability using CCK-8 assay at 0, 24, 48, and 72h. GBM cells were treated with DMSO or DB2313 (10mg/mL). EdU assays were performed using an EdU assay kit with GBM cells seeded in well plates at 2×105 cells per well. 2×104 GBM cells were used for the Transwell assay. A total of 2×105 GBM cells were cultured in spheroid formation ECM for 72h to generate tumor spheroids and used for the 3D tumor spheroid invasion assay with a 96-well 3D spheroid BME cell invasion assay kit. Images were taken at 0, 24, 48, and 72h using microscope. |
Reaction Conditions | 10μg/ml; 72h |
Applications | DB2313 significantly inhibited the proliferation, migration, and invasion of GBM cells (U118MG and U87MG). |
| Animal experiment [2]: | |
Animal models | Female wild-type BALB/c mice |
Preparation Method | Female wild-type BALB/c mice were housed under specific pathogen-free conditions and maintained on a 12-hour day-night cycle with water and regular chow available ad libitum. Mice were treated intranasally with house dust mite (HDM; Dermatophagoides pteronyssinus) extract (25µg in 30µL PBS or saline (vehicle), 5 days per week for 3 weeks. One group of HDM-treated mice were treated with DB2313 (8mg/kg in PBS). Bronchoalveolar lavage fluid was collected. Mucus-secreting cells (MSCs) were stained and counted. Collagen was stained and analyzed. Airway hyperresponsiveness was assessed using the forced oscillation technique. |
Dosage form | 8mg/kg; intranasal administration; 5 days/week for 3 weeks |
Applications | DB2313 decreased airway mucus-secreting cell numbers and small airway collagen deposition, and significantly reduced airway hyperresponsiveness in a house dust mite (HDM)-induced experimental asthma mouse model. |
References: | |
| Cas No. | 2170606-74-1 | SDF | |
| Formula | C42H41FN8O2 | M.Wt | 708.83 |
| Solubility | DMSO : 3.7 mg/mL (5.22 mM; ultrasonic and warming and heat to 70°C) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4108 mL | 7.0539 mL | 14.1078 mL |
| 5 mM | 282.2 μL | 1.4108 mL | 2.8216 mL |
| 10 mM | 141.1 μL | 705.4 μL | 1.4108 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 16 reference(s) in Google Scholar.)